The phrase "aggressive uterine" is grammatically correct and can be used in written English.
It may be used in a medical or biological context to describe a condition or behavior related to the uterus that is forceful or intense.
Example: "The patient was diagnosed with an aggressive uterine fibroid that required immediate attention."
Alternatives: "intense uterine" or "forceful uterine".
Uterine serous carcinomas (USCs) are an aggressive form of uterine cancer that may rely on HER2/neu amplification as a driver of proliferation.
According to a new report published in JAMA Oncology, women with BRCA1 mutations have a higher risk of developing an aggressive type of uterine cancer.
This is documented by the relationship between the five most highly overexpressed microRNAs and a downregulated group of target genes that are related to cellular structure, extracellular matrix and cell proliferation, a signature that can be related to the slow growth and non aggressive behavior of uterine ULMs.
Highly aggressive and malignant uterine leiomyosarcomas are not generally considered to develop from benign leiomyomas.
Type 2 encompassed the more uncommon and highly aggressive types of uterine cancer.
According to these previous studies, the activation of mitogenic signals may be involved in the aggressive behaviour of uterine endometrial cancer.
In a recently published study in the Proceedings of the National Academy of Sciences USA, Lee and colleagues [ 7] report a novel chromosomal aberration in this particularly aggressive form of uterine sarcoma.
Our results presented here are the first to demonstrate that analysis of expression levels of RCAS1 can provide clinical information related to the aggressive behaviour of uterine endometrial cancer.
This would allow more aggressive options such as uterine artery embolization, laparotomy with hemostatic sutures or hysterectomy, if still needed, to be done on a more stable patient.
This is novel, direct evidence that VEGF-C might contribute to the aggressive lymphangitic metastasis in uterine cervical cancers, and that the increase in VEGF-C level from primary tumour to metastatic lymph node might be a prognostic indicator.
